Currently, Cyclacel Pharmaceuticals Inc [CYCC] is trading at $12.33, up 272.51%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CYCC shares have gain 266.96% over the last week, with a monthly amount glided 128.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On September 07, 2018, Ladenburg Thalmann initiated with a Buy rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $5 on October 16, 2015. Roth Capital initiated its recommendation with a Buy and recommended $7 as its price target on February 04, 2010. In a note dated August 12, 2008, Piper Jaffray initiated an Buy rating and provided a target price of $5 on this stock.
This stock has fluctuated between a low of $3.08 and a high of $597.60 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Cyclacel Pharmaceuticals Inc [NASDAQ: CYCC] shares were valued at $12.33 at the most recent close of the market. An investor can expect a potential drop of -91.89% based on the average CYCC price forecast.
Analyzing the CYCC fundamentals
Trailing Twelve Months sales for Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC] were 0.01M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 1.29% with Operating Profit Margin at 604.05%, Pretax Profit Margin comes in at 370.24%, and Net Profit Margin reading is 397.48%. To continue investigating profitability, this company’s Return on Assets is posted at -2.24, Equity is -36.41 and Total Capital is -4.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. However, for the 1st resistance point, the stock is sitting at 19.54, and for the 2nd resistance point, it is at 26.74.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC] is 5.60. Also, the Quick Ratio is 5.60, while the Cash Ratio stands at 5.2. Considering the valuation of this stock, the price to sales ratio is 1953.00, the price to book ratio is 3.48.
Transactions by insiders
Recent insider trading involved Lazar David E., Interim CEO, that happened on Feb 26 ’25 when 194.63 million shares were sold.
